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sion.1 Therefore, patients with IBD require lifelong health-
care services including consistent management and regular 
follow-up examinations. IBD has arisen as a socio-economic 
problem in recent years with an increasing incidence and 
prevalence in East Asia.2-4
Steroids, immunomodulators, and/or tumor necrosis 
factor (TNF)-α blockers are commonly used in patients 
with IBD.5,6 The risk of opportunistic infectious diseases is 
increased in patients with IBD due to exogenous immuno-
suppressive medications and also due to the endogenous 
immunosuppressive mechanism of IBD itself.7 In a study 
conducted in the United States, infection was the most com-
mon cause of hospital admission, accounting for 27.5% of all 
patients admitted with IBD; sepsis and pneumonia were the 
leading causes of death.8 The major causes of pneumonia, 
including infection with influenza virus, pneumococcus, and 
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INTRODUCTION 
Ulcerative colitis (UC), CD, and BehÇet disease (BD) are 
chronic IBD with unidentified causes. The clinical manifes-
tations of these diseases vary from intestinal symptoms such 
as diarrhea, abdominal pain, or intestinal hemorrhage, to ex-
tra-intestinal symptoms such as arthritis, ocular symptoms, 
or skin manifestations. IBD is characterized by a relatively 
early age of onset and chronic repeated relapse and remis-
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other bacterial species, could be prevented with appropriate 
vaccination.9 Therefore, several clinical practice guidelines 
for IBD patients recommend annual vaccination.7 However, 
both doctors and patients have overlooked the importance 
of vaccination in clinical practice. In addition, the status of 
vaccination in IBD patients has been insufficiently investi-
gated in Korea.
Complementary and alternative medicine (CAM) includes 
a wide range of treatments with different definitions. The Na-
tional Center for Complementary and Alternative Medicine 
(NCCAM) has defined CAM as a group of diverse medical 
and healthcare systems, practices, and products that are 
not presently considered a part of conventional medicine.10 
Despite the use of various medications such as steroids, im-
munomodulators, and TNF-α blockers, symptoms are only 
partially controlled in some patients. Many CAM treatments 
for IBD have not yet been medically proven. However, many 
people believe that CAM treatments are less toxic and con-
siderably safer than the standard medical treatment and this 
has generated growing interest and increased usage.11 Some 
studies report that 21−60% of IBD patients in Western coun-
tries use CAM treatments.1,12 However, there has been little 
investigation of the use of CAM by IBD patients in Korea, 
probably due to a lack of interest by physicians. We therefore 
performed this study to investigate the status and patient 
awareness of vaccination and CAM use in IBD patients. 
METHODS
1. Patients and Survey
The survey included IBD patients who attended an educa-
tional session held at the Severance Hospital, Yonsei Univer-
sity College of Medicine on March 23, 2013. The aim of the 
survey was to examine the experiences of vaccination and 
CAM use in patients diagnosed with UC, CD, or BD. Of the 
219 patients who attended the education session, 120 com-
pleted the questionnaire. The survey questionnaire com-
prised vaccination-related items and CAM-related items. 
Vaccination-related items included the awareness of the 
importance of vaccination in IBD patients, whether the pa-
tient had received an explanation of the importance of vac-
cination from physicians, vaccination history, and reasons 
for refusing vaccination. Regarding types of vaccinations, re-
spondents were able to choose from multiple answers: vac-
cines for hepatitis A virus, hepatitis B virus, pneumococcus, 
human papillomavirus, influenza and herpes zoster. CAM-
related items included questions on whether the patients 
had taken CAMs, the purchase route, the reasons for CAM 
treatment, and subjective effectiveness. 
This study was performed following institutional review 
board (IRB) approval (4-2013-0811) from Severance Hospi-
tal. 
2. Statistical Analysis
The chi-square test was used for the analysis of categorical 
data between groups. One-way ANOVA was used to analyze 
differences in continuous variables. Differences were consid-
ered statistically significant at P<0.05. All statistical analyses 
were performed using SPSS Statistics 17.0 software (SPSS 
Inc., Chicago, IL, USA).
RESULTS
1. Baseline Characteristics of Patients
The mean age of the 120 sur vey respondents was 
Table 1. Baseline Characteristics of the Patients
UC CD BD Total P-value
Number (%) 47 (39.2) 55 (45.8) 18 (15.0) 120
Sex (male:female) 32:14 39:16 5:13 76:43* 0.002 
Age (mean±SD) 47.1±15.6 34.1±12.4 46.9±10.6 41.1±14.9 <0.001 
    Male 49.8±16.3 36.1±16.2 47.2±5.4 41.2±15.4 <0.001 
    Female 40.7±11.8 33.3±10.6 46.8±12.2 40.9±14.1 0.125 
Family history of IBD, n (%) 0.922 
    Yes 6 (12.8) 5 (9.1) 2 (11.1) 13 (10.8)
    No 41 (87.2) 50 (90.9) 16 (88.9) 107 (89.2)
*One patient did not reply.
BD, Behçet disease.
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41.1±14.9 years. There were 76 men (63.3%) and 43 women 
(35.8%) (1 patient did not answer the question about sex). 
The most common form of IBD was CD in 55 patients 
(45.8%), followed by UC in 47 patients (39.2%) and BD in 
18 patients (15%). There were 32 (69.6%) male UC patients 
and 14 (30.4%) female UC patients, with 1 non-respondent 
(2.1%); 39 (70.9%) male CD patients and 16 (29.1%) female 
CD patients; and 5 (27.8%) male BD patients and 13 (72.2%) 
female BD patients. The mean age was 47.1±15.6 years in 
the UC patients, 34.1±12.4 years in the CD patients, and 
46.9±10.6 years in the BD patients. Thirteen patients (10.8%) 
had a family history of IBD and 107 patients (89.2%) had no 
family history of IBD (Table 1).
Table 2. The Results of the Survey on Vaccination
UC CD BD Total P-value
Number (%) 47 (39.2) 55 (45.8) 18 (15.0) 120
Awareness on the importance of vaccination 0.856
    Yes 31 (66.0) 36 (65.5) 10 (55.6) 77 (64.2)
    No 13 (27.6) 17 (30.9) 6 (33.3) 36 (30.0)
    No reply 3 (6.4) 2 (3.6) 2 (11.1) 7 (5.8)
Whether they had received information about vaccination by a physician 0.209
    Yes 15 (31.9) 18 (32.7) 2 (11.1) 35 (29.2)
    No 30 (63.8) 37 (67.3) 15 (83.3) 82 (68.3)
    No reply 2 (4.3) 0 (0.0) 1 (5.6) 3 (2.5)
Vaccination history 0.250
    Yes 31 (66.0) 28 (50.9) 12 (66.7) 71 (59.2)
    No 16 (34.0) 27 (49.1) 6 (33.3) 49 (40.8)
Type of vaccination (duplicates allowed)
    Hepatitis A 8 (17.0) 8 (14.5) 3 (16.7) 19 (15.8)
    Hepatitis B 17 (36.2) 9 (16.4) 10 (55.6) 36 (30.0)
    Pneumococcus 2 (4.3) 1 (1.8) 2 (11.1) 5 (4.2)
    Human papillomavirus 1 (2.1) 0 (0.0) 1 (5.6) 2 (1.7)
    Influenza 22 (46.8) 21 (38.2) 10 (55.6) 53 (44.2)
    Herpes zoster 1 (2.1) 5 (9.1) 1 (11.1) 7 (5.8)
Reasons against vaccination (n=49) 
    Afraid of adverse events 1 (6.3) 4 (14.8) 0 (0.0) 5 (10.2)
    Ineffectiveness 0 (0.0) 4 (14.8) 1 (16.7) 5 (10.2)
    Oblivion 8 (50.0) 13 (48.1) 2 (33.3) 23 (46.9)
    Others 4 (25.0) 1 (3.7) 2 (33.3) 7 (14.3)
    No response 3 (18.8) 5 (18.5) 1 (16.7) 9 (18.4)
Values are presented as mean±SD or n (%).
BD, Behçet disease.
Fig. 1. Number of patients with IBD who received vaccinations and that 
of patients aware of the importance of vaccination.
http://dx.doi.org/10.5217/ir.2014.12.2.124 • Intest Res 2014;12(2):124-130
127www.irjournal.org
2. Vaccination
The response to the question “vaccination is more impor-
tant in IBD patients than healthy individuals” was “yes” in 77 
(64.2%) patients and “no” in 36 (30.0%) patients; 7 patients 
(5.8%) did not reply. Among the UC patients, 31 (66.0%) an-
swered “yes,” 13 (27.7%) answered “no,” and 3 (6.4%) did not 
reply to this question. Among the CD patients, 36 (65.5%) 
answered “yes,” 17 (30.9%) answered “no,” and 2 (3.6%) did 
not reply to this question. Among the BD patients, 10 (55.6%) 
answered “yes,” 6 (33.3%) answered “no,” and 2 (11.1%) did 
not reply to this question. No statistical difference was found 
between the diseases. Thirty-five patients (29.2%) reported 
that they had been informed by their physicians of the ne-
cessity of vaccination, whereas 82 patients (68.3%) had not 
been informed. Among those who were informed, 15 had 
UC (31.9%), 18 had CD (32.7%), and 2 had BD (11.1%). Pa-
tients who had not been informed about vaccination by their 
physicians were asked to answer further questions on the al-
ternative sources of information on vaccination. Twenty-one 
patients (52%) responded that they received information 
through the internet and 10 (22%) through an IBD patients’ 
association. However, physician-delivered information on 
the vaccination was not significantly different between dis-
ease groups (P =0.209). Of all the respondents, 54 patients 
(70.1%) were aware of the importance of the vaccination, 
whereas 15 patients (41.7%) were unaware. The vaccination 
rate was significantly higher in patients who were aware of 
the importance of vaccination than in those who were un-
aware (P=0.004; Fig. 1). Excluding vaccinations during child-
hood, 71 respondents (59.2%) had received ≥1 vaccination 
(hepatitis A, hepatitis B, pneumococcus, human papilloma-
virus, influenza, and/or herpes zoster), whereas 49 (40.8%) 
had not. The total vaccination rate was not significantly dif-
ferent among the disease groups. Among those who were 
vaccinated, 19 patients (15.8%) were vaccinated against 
hepatitis A, 36 (30.0%) against hepatitis B, 5 (4.2%) against 
pneumococcus, 2 (1.7%) against human papillomavirus, 53 
(44.2%) against influenza, and 7 (5.8%) against herpes zoster. 
Those who were not vaccinated were asked to state the rea-
Table 3. Types of Complementary and Alternative Medicines 
UC CD BD Total
Number (%) 15/47 (31.9) 14/55 (25.5) 7/18 (38.9) 36/120 (30.0)
Type of CAM, n (%) (duplicates allowed)
    Vitamin complex 3 (20.0) 6 (42.9) 3 (42.9) 12 (33.3)
    Red ginseng 0 (0.0) 7 (50.0) 2 (28.6) 9 (25.0)
    Probiotics 4 (26.7) 1 (7.1) 2 (28.6) 7 (19.4)
    Omega-3 2 (13.3) 1 (7.1) 0 (0.0) 3 (8.3)
    Spirulina 1 (6.7) 0 (0.0) 1 (14.29) 2 (5.6)
    Vegetable decoction 2 (13.3) 0 (0.0) 0 (0.0) 2 (5.6)
    Black garlic extract 0 (0.0) 1 (7.1) 1 (14.29) 2 (5.6)
    Propolis 0 (0.0) 1 (7.1) 1 (14.29) 2 (5.6)
    Enzymes 1 (6.67) 1 (7.1) 0 (0.0) 2 (5.6)
    Calcium 0 (0.0) 1 (7.1) 0 (0.0) 1 (2.8)
    Mugwort 1 (6.67) 0 (0.0) 0 (0.0) 1 (2.8)
    Oriental medicine 1 (6.67) 0 (0.0) 0 (0.0) 1 (2.8)
    Dandelion 1 (6.67) 0 (0.0) 0 (0.0) 1 (2.8)
    Castor oil 0 (0.0) 1 (7.1) 0 (0.0) 1 (2.8)
    Grape juice 0 (0.0) 1 (7.1) 0 (0.0) 1 (2.8)
    Lemon 0 (0.0) 1 (7.1) 0 (0.0) 1 (2.8)
    Ginseng 1 (6.67) 0 (0.0) 0 (0.0) 1 (2.8)
    Honey 0 (0.0) 0 (0.0) 1 (14.29) 1 (2.8)
    Moxa cautery 0 (0.0) 1 (7.1) 0 (0.0) 1 (2.8)
BD, Behçet disease; CAM, complementary and alternative medicine.
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son for the non-vaccination. Twenty-three patients (46.9%) 
replied that had forgotten the type of vaccination, 5 (10.2%) 
stated fear of adverse events, 5 (10.2%) thought that vaccines 
were ineffective, 7 patients (14.3%) stated other reasons, and 
9 patients (18.4%) did not reply (Table 2).
3. Complementary and Alternative Medicine 
According to the survey results, 36 patients (30.0%) were 
currently taking a functional health food or folk remedy, 
whereas 84 patients (70.0%) were not. Of the 36 patients us-
ing a CAM, the most common was vitamins in 12 (33.0%) 
patients, followed by red ginseng in 9 (25.0%) and probiotics 
in 7 (19.4%). Other CAM treatments included omega-3 prod-
ucts, spirulina, garlic extract, cabbage decoction, dandelion 
decoction, mugwort, and propolis (Table 3). CAM products 
were purchased directly in 12 patients (33.3%), gifted by 
friends or family members in 15 (41.6%), and purchased 
through the internet in 7 (19.4%). Considering the reason for 
CAM use, 14 patients (38.9%) stated improvement in symp-
toms, 15 (41.6%) stated friends’ suggestions, 1 (2.7%) stated 
the media, 2 (5.6%) stated relief of anxiety, 4 (11.1%) stated 
other reasons, and 7 (18.9%) did not respond. CAM use was 
found to be subjectively effective in 20 patients (55.6%) and 
subjectively ineffective in 6 patients (16.7%); 10 patients 
(27.8%) did not answer this question (Table 4).
DISCUSSION
Our study aimed to develop strategies for the improve-
ment in vaccination and CAM use in Korean patients with 
IBD in actual clinical setting based on the survey results. 
Immunosuppression may occur as a result of treatment in 
IBD patients due to the use of immunomodulators or as a 
result of underlying disease, thus increasing susceptibility 
to opportunistic infection. Therefore, the importance of vac-
cination should be emphasized more in IBD patients than 
in other patients. However, it is often overlooked, not only 
by patients but also by physicians.13,14 According to a study 
performed in the United States, 86% of patients with IBD re-
ceived immunosuppressive treatment. In contrast, only 28% 
were vaccinated against influenza and only 9% against pneu-
Table 4. Results of Survey on Complementary and Alternative Medicine Use
UC CD BD Total
Number 47 55 18 120
Previous experience with CAM, n (%)
    Yes 15 (31.9) 14 (25.5) 7 (38.9) 36 (30.0)
    No 32 (68.1) 41 (74.5) 11 (61.1) 84 (70.0)
Purchase route (n=36)
    Direct 5 (33.3) 5 (35.7) 2 (28.6) 12 (33.3)
    Gift 7 (46.7) 6 (42.9) 2 (28.6) 15 (41.7)
    Internet 3 (20.0) 2 (14.3) 2 (28.6) 7 (19.4)
    No reply 0 (0.0) 1 (7.1) 1 (14.2) 2 (5.6)
Reason for taking CAM (n=36)
    Expectation of efficacy 7 (46.7) 6 (42.9) 1 (14.3) 14 (38.9)
    Friends’ advice 7 (46.7) 5 (35.7) 3 (42.9) 15 (41.6)
    Media advertisement 0 (0) 0 (0) 1 (14.3) 1 (2.8)
    Relief of anxiety 0 (0) 1 (7.1) 1 (14.3) 2 (5.6)
    Others 1 (6.6) 2 (14.3) 1 (14.3) 4 (11.1)
Subjective effectiveness of CAM (n=36)
    Yes 7 (46.7) 11 (78.6) 2 (28.6) 20 (55.6)
    No 5 (33.3) 1 (7.1) 0 (0.0) 6 (16.7)
    No reply 3 (20.0) 2 (14.3) 5 (71.4) 10 (27.7)
Values are presented as mean±SD or n (%).
BD, Behçet disease; CAM, complementary and alternative medicine.
http://dx.doi.org/10.5217/ir.2014.12.2.124 • Intest Res 2014;12(2):124-130
129www.irjournal.org
mococcus.15,16 A Korean study showed similar results, with a 
low vaccination rate (37.5% with the influenza vaccine and 
6.3% with the pneumococcal vaccine).17 In our study, the 
vaccination rates were 44.2% with the influenza vaccine and 
5% with the pneumococcal vaccine, which were comparable 
with previous results. Hepatitis A, hepatitis B, and human 
papillomavirus vaccination rates were even lower, ranging 
between 1.7% and 29.2%.
Rheumatoid arthritis shares similar characteristics with 
IBD in that both are immune disorders and require the use 
of steroids and TNF-α blockers. According to the results of a 
German cohort study on patients with rheumatoid arthritis 
and IBD, the proportion of patients aware of the importance 
of vaccination and those who received information from 
doctors (rheumatology specialists, general physicians) on 
the need for vaccination were 78.4% and 44.2%, respectively; 
both these values are higher than those found in our study.18 
The actual vaccination rate was also higher than that in our 
study; 65.3% with the influenza vaccine and 65.3% with the 
pneumococcal vaccine. According to subgroup analysis, the 
patient group most aware of the need for vaccination (age 
≥60 years, use of anti-TNF agent or rituximab) had a higher 
pneumococcal vaccination rate.18 Similarly, in our study the 
vaccination rate was also higher in the patients who were 
aware of the importance of vaccination.
A recent study performed in the United States proposed 
that the vaccination rate for influenza and pneumococcus 
could be enhanced systematically, for example by keeping 
medical records of medications and vaccination status, and 
by providing repeated education targeting patients as well 
as healthcare providers.19 Likewise, checking each patient’s 
vaccination status regularly at outpatient clinics is crucial to 
increase the vaccination rate.
In our survey, 36 patients (30.0%) responded that they 
were current users of CAMs, mostly oral products. This result 
is comparable to that of a previous Korean study in patients 
with stomach cancer.20 In a New Zealand study on IBD pa-
tients, the most common CAM was oral products, as in our 
study. However, in a German study, the most common CAM 
was homeopathy, accounting for 52.9%.1,11 This difference 
can be attributed to differing cultural backgrounds and types 
of traditional CAMs.
The reason for CAM use was mostly due to friends and 
family members in our study. Despite the subjective effec-
tiveness reported by >50% of respondents, this raises a par-
ticular concern that patients have not discussed the use of 
CAM with their doctors. Thus, they may be receiving inaccu-
rate information on CAMs, which could result in interaction 
with other medications and cause adverse events. Therefore, 
physicians should be more aware of current CAM use in 
patients and provide objective and accurate information to 
patients. 
Patients are vulnerable to unfiltered information provided 
through the internet and mass media. Lack of proper educa-
tion and provision of inaccurate information may lead to 
psychological instability and anxiety about medications and 
surgical procedures important to the treatment of IBD. In 
our study, the proportion of patients who obtained medical 
information from the internet rather than from their physi-
cians was high. Therefore, educational sessions and academ-
ic symposiums held by hospitals and academic institutes 
will provide IBD patients with knowledge and understand-
ing.
There are some limitations to this study. Since the survey 
results were acquired from a single tertiary hospital, selec-
tion and recall biases are inevitable. The proportion of CD 
patients was higher than that of the UC patients, and this 
does not reflect the relative prevalences of types of IBD in 
Korea. This finding may indicate indirectly that CD patients 
are more interested in the education sessions. In addition, 
the authors were unable to analyze other objective data in-
cluding disease status, current medication, serological test 
results before vaccination, and infection history, due to the 
anonymous conditions of the survey. Since patients who 
already had antibodies against hepatitis A and B would not 
have received additional vaccinations, the exact vaccination 
rate could be slightly lower than that recorded here. More-
over, determination of the overall frequency of use of probi-
otics in IBD patients could be inaccurate because we were 
unable to ascertain whether probiotics were prescribed by 
physicians. Finally, data on the socioeconomic status of pa-
tients were limited. Additional studies are needed to further 
investigate the efficacy, safety, and predictive factors for the 
use of CAMs.
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